Inequality of pandemic proportions: State and pharma failures not to be repeated
As the COVID-19 pandemic enters its fourth year, this report identifies four key lessons from the failure of States and pharmaceutical companies to comply with their human rights obligations and responsibilities to ensure fair access to COVID-19 vaccines globally.
Post-implementation review of the Seventh Community Pharmacy Agreement
This review report provides an overview of the context in which Community Pharmacy Agreements have developed over time and an analysis of the impacts of specific changes made by the Seventh Community Pharmacy Agreement in respect of pharmacy remuneration, wholesale supply and distribution arrangements, and...
Antimicrobial resistance: the silent global pandemic
Antimicrobial resistance is one of the most serious global public health threats of the 21st Century. This paper argues that now is the time for strong and sustained action on antimicrobial resistance, as this may well be the cause of the next global pandemic.
Traditional Human Immunodeficiency Virus treatment and family and social influence as barriers to accessing HIV care services in Belu, Indonesia
Access to HIV care services, including antiretroviral therapy (ART), is essential for improving health outcomes of people living with HIV (PLHIV) and reducing HIV transmission and AIDS-related deaths. As a part of a qualitative study in Belu, this paper describes the use of traditional medicines...
Contemporary community pharmacy practice: white paper
The Pharmaceutical Society of Australia has launched its first contemporary community pharmacy practice white paper, which highlights three key elements of consideration which form the foundation of a viable and sustainable contemporary community pharmacy practice.
Pharmac Review: final report
This final review report recommends some current roles undertaken by Pharmac would be better advanced by other agencies, namely what goes on to the vaccination schedule, cataloguing and contracting of medical devices, and holding the leadership role in promoting responsible use of pharmaceuticals.
The Australian Nuclear Science and Technology Organisation’s management of nuclear medicine assets
This audit examines the effectiveness of the Australian Nuclear Science and Technology Organisation’s management of assets involved in the manufacture, production and distribution of nuclear medicines.
The firm and the FDA: McKinsey and Company’s conflicts of interest at the heart of the opioid epidemic
The Committee’s investigation has uncovered significant, years-long conflicts of interest at McKinsey, resulting from its work for the federal government at the same time it was advising opioid manufacturers, including providing advice on how to influence the regulatory decisions of the U.S. Food and Drug...
Vaccine related fraud and security risks: final report
This inquiry was established to to identify and address any vulnerabilities that had or potentially could emerge, in relation to vaccine and vaccine related fraud and security, and provide the Australian public with confidence in the integrity of the COVID-19 vaccination program.
Money calls the shots: pharma's response to the COVID-19 vaccines crisis
This report argues that, despite receiving billions in public funding, a number of pharmaceutical companies are continuing to put their own business interests before their human rights responsibilities by creating barriers to fair access to their COVID-19 vaccines through their decisions not to share intellectual...
Pharmac Review: interim report
This interim report reviews the performance of New Zealand's medicines procurement agency, Pharmac.
National baseline report on Quality Use of Medicines and Medicines Safety - Phase 1: residential aged care
This report identifies a potential roadmap to embed Quality Use of Medicine principles in the aged care sector, with the aim of reducing medication-related harm.
The new frontier - delivering better health for all Australians
This report examines the opportunities to deliver better health care for Australians through our regulatory and health technology assessment process for both medicines and technologies.
Funding rare disease therapies in Australia: 2021 progress update
For the 2 million Australians living with rare diseases, access to medicines can be inadequate. This report reassesses 2014 research by the McKell Institute, assessing the state of rare disease therapies in Australia.
National Aged Care Mandatory Quality Indicator Program (QI Program) Manual 2.0 – Part B
This manual is for government-subsidised residential aged care providers. Part B includes a range of tools and resources to support continuous quality improvement for each of the QI Program quality indicators.
A double dose of inequality: pharma companies and the COVID-19 vaccines crisis
This report focuses on six leading vaccine developers, assessing each company’s human rights policy, pricing structure, records on intellectual property, knowledge and technology sharing, allocation of available vaccine doses and transparency.
COVID-19 procurements and deployments of the National Medical Stockpile
This audit is one of five performance audits conducted under phase one of the ANAO’s multi-year strategy that focuses on the effective, efficient, economical and ethical delivery of the Australian Government’s response to the COVID-19 pandemic, and the second of two performance audits focused on...
The science of immunisation: questions and answers
This guide, developed in partnership with the federal Department of Health, answers common questions about immunisation.
s100 Survey report: HIV antiretroviral (ART) co-payment initiative
In October 2015, the NSW government enacted its pre-election commitment to waive the PBS co-payment for s100 HIV medications in NSW. This report describes respondents' experiences of the co-payment waiver.
Planning and governance of COVID-19 procurements to increase the National Medical Stockpile
This audit examined whether the COVID-19 National Medical Stockpile (NMS) procurement requirement was met through effective planning and governance arrangements.
Patient power: unleashing choice over routine medications
This report finds that many patients are not fully aware of the level of control they are entitled to when it comes to choosing medication. It suggests that pharmacists could play a greater role in the patient care pathway to support patients make choices about...
Rationalising regulation: helping the economy recover from the corona crisis
Australia’s anachronistic, inconsistent and excessive regulatory landscape is an area of immense potential for growth-enhancing economic reforms. This paper considers regulations across a wide range of sectors, including the construction, agricultural, pharmaceutical, retail trade, mining, hospitality and tourism, and childcare sectors.
Quality Use of Medicines and Medicines Safety discussion paper for public consultation – Phase 1: aged care
The Commission are developing a National Baseline Report on Quality Use of Medicines and Medicines Safety in response to this initiative. This discussion paper was published to support the public consultation which informed Phase 1 of the National Baseline Report.
Biodata and biotechnology: opportunity and challenges for Australia
This report canvasses the extraordinary recent developments in genome sequencing and genetic engineering, which will transform all biological enterprises, including healthcare, among the most important parts of the global economy. It argues that there is a opportunity for Australia to play a leading role in...
Fact Check Fact File: The history of vaccines, from smallpox to SARS and beyond
With the world focused on a fast-tracked treatment for the novel coronavirus, RMIT ABC Fact Check takes a look at the history of vaccine development in the fight against some of the world's most infectious diseases.